Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain

Milligan, K. A.; Lantéri-Minet, Michel; Borchert, Klaus; Helmers, Henk; Donald, Royden; Kress, Hans G.; Adriàensen, H.; Moulin, Dwight E.; Järvimäki, Voitto; Haazen, L.

doi:10.1054/jpai.2001.25352

Cited by 90 publications

(71 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Discontinuation of fentanyl administration induces a withdrawal syndrome and a delayed discharge from the hospital compared to when other analgesic narcotics are used (Arnold et al 1990;Dominguez et al 2003;Franck and Vilardi 1995;Franck et al 1998Franck et al , 2004. It has been estimated that 1 to 3% of patients treated with opioids for chronic pain develop an opioid addiction (Cowan et al 2003;Milligan et al 2001). This percentage may be higher in patients with a history of drug abuse or other psychiatric disorders (Chabal et al 1997;Katon et al 1985;Schieffer et al 2005).…”

Section: Introductionmentioning

confidence: 99%

The effects of buprenorphine on fentanyl withdrawal in rats

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

The effects of buprenorphine on fentanyl withdrawal in rats

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Due to these properties, the fentanyl skin patch is regarded as having a low risk of leading to tolerance development or physiological dependence (11). One study of 532 patients with non-cancer chronic pain determined no misuse or physiological dependence in any patient (12). The risk of dependence in patients using it for the treatment of cancer pain is suggested as being very low (10).…”

Section: Discussionmentioning

confidence: 99%

Fentanyl dependence associated with the use of transdermal fentanyl in a cancer patient: a case report

Sarısoy¹,

Korkmaz²,

Özturan³

et al. 2013

Dusunen Adam

View full text Add to dashboard Cite

Fentanyl dependence associated with the use of transdermal fentanyl in a cancer patient: a case report Fentanyl is a syntetic narcotic analgesic that is available for the management of chronic cancer and noncancer pain. Its analgesic potency is 75-100 times greater than that of morphine. Apart from the lipofilic nature and the high potency, fentanyl is characterized by low molecular weight and thus, is suitable for transdermal use. The transdermal fentanyl patches are designed to deliver fentanyl at a constant rate for periods of 72 hours. Patches with a delivery rate of 25, 50, 75 and 100 µ/h are avaiable. Transdermal fentanyl is effective and safe in many cancer patients. Abuse/misuse of fentanyl patches has been increasingly reported along with different routes of administration such as intravenous, oral, rectal, inhalational use.However, there are two reports associated with transdermal fentanyl dependency in literature. Here, we report a case of fentanyl dependence associated with the use of transdermal fentanyl in a cancer patient.

show abstract

“…Of the 57 % who completed this trial, 86 % preferred transdermal fentanyl and 67 % reported good to moderate pain relief. There was a 25 % attrition rate due to adverse effects [20].…”

Section: Fentanylmentioning

confidence: 99%

Evidence-Based Treatment for Chronic Pain with Opioids

Staats

2016

Controlled Substance Management in Chronic Pain

View full text Add to dashboard Cite

Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain

Cited by 90 publications

References 22 publications

The effects of buprenorphine on fentanyl withdrawal in rats

The effects of buprenorphine on fentanyl withdrawal in rats

Fentanyl dependence associated with the use of transdermal fentanyl in a cancer patient: a case report

Evidence-Based Treatment for Chronic Pain with Opioids

Contact Info

Product

Resources

About